<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Ir J Med Sci</journal-id><journal-id journal-id-type="iso-abbrev">Ir J Med Sci</journal-id><journal-title-group><journal-title>Irish Journal of Medical Science</journal-title></journal-title-group><issn pub-type="ppub">0021-1265</issn><issn pub-type="epub">1863-4362</issn><publisher><publisher-name>Springer International Publishing</publisher-name><publisher-loc>Cham</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39516335</article-id><article-id pub-id-type="pmc">PMC11861117</article-id>
<article-id pub-id-type="publisher-id">3827</article-id><article-id pub-id-type="doi">10.1007/s11845-024-03827-x</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Application of norepinephrine in the treatment of septic shock: a meta-analysis</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Xu</surname><given-names>Qiu Ying</given-names></name><address><email>xuqiuying3271@163.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Jin</surname><given-names>Yan Hong</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Fu</surname><given-names>Li</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Ying Ying</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1"><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/013xs5b60</institution-id><institution-id institution-id-type="GRID">grid.24696.3f</institution-id><institution-id institution-id-type="ISNI">0000 0004 0369 153X</institution-id><institution>Department of Intensive Care Unit, Beijing Friendship Hospital, </institution><institution>Capital Medical University, </institution></institution-wrap>No. 95 Yong&#x02019;an Road, Xicheng District, Beijing, 100050 China </aff></contrib-group><pub-date pub-type="epub"><day>9</day><month>11</month><year>2024</year></pub-date><pub-date pub-type="pmc-release"><day>9</day><month>11</month><year>2024</year></pub-date><pub-date pub-type="ppub"><year>2025</year></pub-date><volume>194</volume><issue>1</issue><fpage>361</fpage><lpage>369</lpage><history><date date-type="received"><day>20</day><month>8</month><year>2024</year></date><date date-type="accepted"><day>18</day><month>10</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><sec><title>Objective</title><p id="Par1">To systematically evaluate the efficacy and safety of norepinephrine in the treatment of septic shock.</p></sec><sec><title>Methods</title><p id="Par2">Literature retrieval of eligible randomized controlled trials (RCTs) on norepinephrine in the treatment of septic shock was performed in three English databases including PubMed, Web of Science, and Medline from database establishment to October 1, 2023. The Cochrane risk bias tool was used to evaluate the quality of the included literature. RevMan 5.3 software was used for meta-analysis.</p></sec><sec><title>Results</title><p id="Par3">A total of 14 RCTs were included in this study, and the risk of bias was low. Our meta-analysis showed that the norepinephrine group had significantly better outcomes in reducing the 28-day mortality rate (RR&#x02009;=&#x02009;0.92; 95% CI, 0.86&#x02009;~&#x02009;0.99; <italic>P</italic>&#x02009;=&#x02009;0.03), the incidence of arrhythmia (RR&#x02009;=&#x02009;0.54; 95% CI, 0.45&#x02009;~&#x02009;0.64; <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001), and the length of stay in intensive care unit (ICU) (MD&#x02009;=&#x02009;&#x02009;&#x02212;&#x02009;1.03; 95% CI,&#x02009;&#x02212;&#x02009;1.85 to approximately&#x02009;&#x02212;&#x02009;0.21; <italic>P</italic>&#x02009;=&#x02009;0.01) than those of the control group. However, there were no statistically significant differences in in-hospital mortality rate (RR&#x02009;=&#x02009;0.97; 95% CI, 0.90&#x02009;~&#x02009;1.04; <italic>P</italic>&#x02009;=&#x02009;0.4), the 90-day mortality rate (RR&#x02009;=&#x02009;1.07; 95% CI, 0.97&#x02009;~&#x02009;1.18; <italic>P</italic>&#x02009;=&#x02009;0.15), length of hospital stay (MD&#x02009;=&#x02009;0.03; 95% CI,&#x02009;&#x02212;&#x02009;1.13&#x02009;~&#x02009;1.18; <italic>P</italic>&#x02009;=&#x02009;0.96), and the rate of achieving target MAP (RR&#x02009;=&#x02009;1.27; 95% CI, 0.72&#x02009;~&#x02009;2.26; <italic>P</italic>&#x02009;=&#x02009;0.41) between the norepinephrine group and the control group.</p></sec><sec><title>Conclusion</title><p id="Par4">Norepinephrine has the advantages of improving 28-day mortality, shortening ICU hospitalization time, and reducing the incidence of arrhythmia. It is a more effective choice for the treatment of septic shock than other vasopressors, and the incidence of arrhythmia is low.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Meta-analysis</kwd><kwd>Norepinephrine</kwd><kwd>Randomized controlled trial</kwd><kwd>Septic shock</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Royal Academy of Medicine in Ireland 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par5">Sepsis remains a serious cause of morbidity and mortality in critically ill patients worldwide, despite the use of broad-spectrum antibiotics, advanced intensive care unit (ICU) management, as well as resuscitation strategies and protocols [<xref ref-type="bibr" rid="CR1">1</xref>]. The global burden of sepsis is estimated at&#x02009;&#x0003e;&#x02009;19 million cases each year and 5 million sepsis-related deaths annually, especially in low-income and middle-income countries [<xref ref-type="bibr" rid="CR2">2</xref>]. Septic shock, the most severe complication of sepsis, accounts for 10% of all admissions to the ICU, with a related mortality rate of 40&#x02013;60% [<xref ref-type="bibr" rid="CR3">3</xref>]. Septic shock is now defined as a life-threatening organ dysfunction caused by a dysregulated host response to infection [<xref ref-type="bibr" rid="CR4">4</xref>]. It is mainly manifested as severe hypotension with low systolic blood pressure&#x02009;&#x02264;&#x02009;90 mmHg (or mean arterial blood pressure&#x02009;&#x02264;&#x02009;65 mmHg), accompanied by hypoperfusion [<xref ref-type="bibr" rid="CR5">5</xref>].</p><p id="Par6">The current practice in the treatment of sepsis is to improve tissue oxygenation and perfusion in patients, along with appropriate administration of antibiotics against pathogenic microorganisms. According to Guidelines 2021 for sepsis [<xref ref-type="bibr" rid="CR6">6</xref>], for adult septic shock patients, it is recommended to prioritize norepinephrine as a vasopressor rather than other vasopressor agents, and adrenaline or dopamine can be used as an alternative option in cases where norepinephrine cannot be obtained. Meanwhile, vasopressors should be immediately initiated in severe hypotension with life-threatening septic shock [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. For septic shock, vasoactive agents are an important means of maintaining hemodynamic stability and ensuring perfusion of major organs [<xref ref-type="bibr" rid="CR7">7</xref>].</p><p id="Par7">A previous meta-analysis in 2018 analyzed outcomes such as oxygen transport, oxygen consumption, cardiac index, cardiac ratio, MAP, mean pulmonary artery pressure, central venous pressure, and systemic vascular resistance index to clarify the role of norepinephrine and other vasoactive agents in maintaining hemodynamic stability and ensuring perfusion of major organs [<xref ref-type="bibr" rid="CR9">9</xref>]. In order to further investigate the differences in efficacy and safety between norepinephrine and other vasoactive agents or placebo in patients with septic shock, the present study included more updated trials for meta-analysis on the patients&#x02019; outcomes, such as mortality rate, length of hospital stay, and incidence of adverse events. Add more references for norepinephrine and other vasoactive drugs or placebos in the treatment of patients with septic shock in efficacy and safety.</p></sec><sec id="Sec2"><title>Materials and methods</title><sec id="Sec3"><title>Retrieval strategies</title><p id="Par8">A systematic literature retrieval was performed in three English databases including PubMed, Web of Science, and Medline from database establishment to October 1, 2023, using the keywords &#x0201c;semantic shock&#x0201d; OR &#x0201c;sepsis&#x0201d; OR &#x0201c;multiple sepsis&#x0201d; OR &#x0201c;imperfect shock&#x0201d; AND &#x0201c;norepinephrine&#x0201d; OR &#x0201c;noradrenaline.&#x0201d; Besides focusing on the retrieval of titles, more literature was searched based on the references of relevant literature retrieved.</p></sec><sec id="Sec4"><title>Inclusion and exclusion criteria</title><p id="Par9">Inclusion criteria are as follows: (1) research type of RCTs; (2) research subjects of patients with septic shock; (3) intervention using norepinephrine, with the use of placebo or other vasopressor agents as the control; and (4) outcome measures of 28-day mortality rate, in-hospital mortality rate, 90-day mortality rate, length of hospital stay, length of stay in ICU, the incidence of arrhythmia, and the rate of achieving target MAP.</p><p id="Par10">Exclusion criteria are as follows: (1) non-population-based study; (2) conference abstracts, case reports, systematic reviews, etc.; (3) insufficient outcome data that cannot be analyzed; (4) duplicates; (5) incomplete studies; (6) non-randomized controlled trials.</p></sec><sec id="Sec5"><title>Literature screening and data extraction</title><p id="Par11">Literature screening was performed independently by two researchers based on inclusion and exclusion criteria. After preliminary screening by reading titles and abstracts, studies that might meet the inclusion criteria were checked through full-text reading. Any disagreement between the two researchers was resolved by discussion until a consensus was reached or by consulting a third researcher. After literature screening, two researchers would extract data (literature information, research type, research time, demographic characteristics of subjects, sample size of two groups, control type, and primary outcome measures) according to the established standard data extraction table.</p></sec><sec id="Sec6"><title>Quality evaluation</title><p id="Par12">The risk of bias assessment of the included studies was assessed using the bias risk assessment tool for RCTs recommended by the Cochrane Guidelines [<xref ref-type="bibr" rid="CR10">10</xref>]. Evaluation of the risk of bias covered seven items including random sequence generation, allocation concealment, blinding of participants, personnel, and outcome assessors, completeness of outcome data, selective reporting of results, and others. The evaluation results of each item were divided into three levels: low risk, unclear, and high risk, and finally represented by a risk of bias graph. Two researchers independently evaluated the risk of bias in the included studies using standardized data extraction tables. Any discrepancies were solved by discussion with a third researcher until consensus was achieved.</p></sec><sec id="Sec7"><title>Statistical analysis</title><p id="Par13">RevMan 5.3 software was used for statistical analysis. For outcome variables (length of hospital stay and length of stay in ICU) calculated using the same criteria among continuous variables, mean difference (MD) was used as the statistical measure, while for the binary variable (28-day mortality rate, in-hospital mortality rate, 90-day mortality rate, incidence of arrhythmia, or the rate of achieving target MAP), the risk ratio (RR) was the statistical measure. The 95% confidence interval (CI) was provided for each statistic. The heterogeneity test was realized by using <inline-formula id="IEq1"><alternatives><tex-math id="M1">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${I}^{2}$$\end{document}</tex-math><mml:math id="M2"><mml:msup><mml:mrow><mml:mi>I</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msup></mml:math><inline-graphic xlink:href="11845_2024_3827_Article_IEq1.gif"/></alternatives></inline-formula> statistics to quantify the heterogeneity. If the hypothesis of homogeneity was not rejected (<inline-formula id="IEq2"><alternatives><tex-math id="M3">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${I}^{2}$$\end{document}</tex-math><mml:math id="M4"><mml:msup><mml:mrow><mml:mi>I</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msup></mml:math><inline-graphic xlink:href="11845_2024_3827_Article_IEq2.gif"/></alternatives></inline-formula> &#x0003c; 50% or <italic>P</italic>&#x02009;&#x0003e;&#x02009;0.1), a fixed-effect model was used for calculation; otherwise, a random-effect model was used due to poor homogeneity (<inline-formula id="IEq3"><alternatives><tex-math id="M5">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${I}^{2}$$\end{document}</tex-math><mml:math id="M6"><mml:msup><mml:mrow><mml:mi>I</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msup></mml:math><inline-graphic xlink:href="11845_2024_3827_Article_IEq3.gif"/></alternatives></inline-formula> &#x0003e; 50% or <italic>P</italic>&#x02009;&#x02264;&#x02009;0.1). The inspection level of the meta-analysis was set at 0.05.</p></sec></sec><sec id="Sec8"><title>Results</title><sec id="Sec9"><title>Literature screening process and results</title><p id="Par14">A total of 685 articles were obtained in initial retrieval, and finally, 14 RCTs were included for meta-analysis after subsequent screenings. The process and results of literature retrieval are shown in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>a.<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p><bold>a</bold> The flow chart of included studies. <bold>b</bold> Risk of bias summary</p></caption><graphic xlink:href="11845_2024_3827_Fig1_HTML" id="MO1"/></fig></p></sec><sec id="Sec10"><title>Basic characteristics of the included studies and assessment of the risk of bias</title><p id="Par15">All 14 eligible RCTs, involving a total of 5028 cases, were included for meta-analysis. Most of the enrolled literature were multicenter studies, primarily conducted in the ICU, with one study involving patients from the emergency department of the hospital. The major subjects included in the study were the population aged 40&#x02013;70 years old. In each study, both the norepinephrine group and the control group included male and female cases, without statistically significant difference in the gender ratio between groups, while a small number of studies did not report the gender ratio of the two groups separately. The controls included in the study used placebo, terlipressin, adrenaline, dopamine, phenylephrine, etc. In addition, the included studies had a lower risk of bias, with the inclusion of subjects randomly during experimental design and evaluation of the efficacy and safety of norepinephrine objectively. Detailed basic characteristics of all the included studies are shown in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref> [<xref ref-type="bibr" rid="CR11">11</xref>&#x02013;<xref ref-type="bibr" rid="CR24">24</xref>], and the assessment of the risk of bias is shown in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>b.<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Characteristics of included studies</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">No</th><th align="left">Country</th><th align="left">Department</th><th align="left">Age of intervention group and control group</th><th align="left">Sample size of intervention group and control group (male/female)</th><th align="left">Control intervention</th><th align="left">Primary outcome</th></tr></thead><tbody><tr><td align="left">A. Morelli, 2008 [<xref ref-type="bibr" rid="CR11">11</xref>]</td><td align="left">Italy</td><td align="left">ICU</td><td align="left">67/66</td><td align="left"><p>14/6</p><p>13/6</p></td><td align="left">Terlipressin</td><td align="left">Hemodynamic changes</td></tr><tr><td align="left">A. Morelli, 2009 [<xref ref-type="bibr" rid="CR12">12</xref>]</td><td align="left">Italy</td><td align="left">ICU</td><td align="left">64/67</td><td align="left"><p>12/3</p><p>10/5</p></td><td align="left">Terlipressin</td><td align="left">Hemodynamic changes</td></tr><tr><td align="left">Annane, 2007 [<xref ref-type="bibr" rid="CR13">13</xref>]</td><td align="left">France</td><td align="left">Multicenter study involving 19 ICUs</td><td align="left">60/65</td><td align="left"><p>99/70</p><p>103/58</p></td><td align="left">Adrenaline&#x02009;&#x000b1;&#x02009;placebo</td><td align="left">28-day all-cause mortality rate</td></tr><tr><td align="left">Choudhury, 2017 [<xref ref-type="bibr" rid="CR14">14</xref>]</td><td align="left">India</td><td align="left">ICU</td><td align="left">48&#x02009;&#x000b1;&#x02009;29.12/46&#x02009;&#x000b1;&#x02009;76.12</td><td align="left"><p>34/8</p><p>35/7</p></td><td align="left">Terlipressin</td><td align="left">Qualified hemodynamics</td></tr><tr><td align="left">De Backer, 2010 [<xref ref-type="bibr" rid="CR15">15</xref>]</td><td align="left">Belgium, Austria, and Spain</td><td align="left">Multicenter study involving 8 ICUs</td><td align="left">67/68</td><td align="left"><p>449/372</p><p>507/351</p></td><td align="left">Dopamine</td><td align="left">28-day mortality rate</td></tr><tr><td align="left">Gordon, 2016 [<xref ref-type="bibr" rid="CR16">16</xref>]</td><td align="left">Britain</td><td align="left">Multicenter study involving 18 ICUs</td><td align="left">66</td><td align="left">238/171</td><td align="left">Antidiuretic hormone</td><td align="left">Days without renal failure within 28 days</td></tr><tr><td align="left">Hajjar, 2019 [<xref ref-type="bibr" rid="CR17">17</xref>]</td><td align="left">Brazil</td><td align="left">ICU</td><td align="left">62/64</td><td align="left"><p>69/56</p><p>68/57</p></td><td align="left">Vasopressin</td><td align="left">28-day mortality rate</td></tr><tr><td align="left">Liu, 2018 [<xref ref-type="bibr" rid="CR18">18</xref>]</td><td align="left">China</td><td align="left">Multicenter study involving 21 ICUs</td><td align="left">61.09/16.20; 60.93/15.86</td><td align="left"><p>169/97</p><p>162/98</p></td><td align="left">Terlipressin</td><td align="left">28-day all-cause mortality rate</td></tr><tr><td align="left">Martin, 1993 [<xref ref-type="bibr" rid="CR19">19</xref>]</td><td align="left">France</td><td align="left">ICU</td><td align="left">52&#x02009;&#x000b1;&#x02009;12/53&#x02009;&#x000b1;&#x02009;19</td><td align="left"><p>12/4</p><p>12/4</p></td><td align="left">Dopamine</td><td align="left">Qualified hemodynamics</td></tr><tr><td align="left">Morelli, 2008 [<xref ref-type="bibr" rid="CR20">20</xref>]</td><td align="left">Italy</td><td align="left">ICU</td><td align="left">70/70</td><td align="left"><p>9/7</p><p>12/4</p></td><td align="left">Phenylephedrine</td><td align="left">Qualified hemodynamics</td></tr><tr><td align="left">Myburgh, 2008 [<xref ref-type="bibr" rid="CR21">21</xref>]</td><td align="left">Australia</td><td align="left">Multicenter study involving 4 ICUs</td><td align="left">60.4&#x02009;&#x000b1;&#x02009;14.8/59.4&#x02009;&#x000b1;&#x02009;15.9</td><td align="left"><p>82/56</p><p>85/54</p></td><td align="left">Adrenaline</td><td align="left">Qualified hemodynamics</td></tr><tr><td align="left">Patel, 2010 [<xref ref-type="bibr" rid="CR22">22</xref>]</td><td align="left">The USA</td><td align="left">ICU</td><td align="left">Unknown</td><td align="left"><p>52/66</p><p>64/70</p></td><td align="left">Dopamine</td><td align="left">28-day all-cause mortality rate</td></tr><tr><td align="left">Permpikul, 2019 [<xref ref-type="bibr" rid="CR23">23</xref>]</td><td align="left">Thailand</td><td align="left">Emergency department</td><td align="left">65/68</td><td align="left"><p>71/84</p><p>77/78</p></td><td align="left">Placebo</td><td align="left">Shock control rate within 6 h</td></tr><tr><td align="left">Russell, 2008 [<xref ref-type="bibr" rid="CR24">24</xref>]</td><td align="left">Canada, Australia, and the USA</td><td align="left">Multicenter study involving 27 hospitals</td><td align="left">61.8&#x02009;&#x000b1;&#x02009;16/59.3&#x02009;&#x000b1;&#x02009;16.4</td><td align="left"><p>229/153</p><p>246/150</p></td><td align="left">Vasopressin</td><td align="left">All-cause mortality rate</td></tr></tbody></table></table-wrap></p><p id="Par16">The risk of included literature was assessed according to the Cochrane bias risk assessment tool. Four articles were rated as high risk of bias, two as moderate risk of bias, and eight as low risk of bias. The literature evaluation basis is as follows: (1) In terms of random sequence generation, 12 reports used the random sequence generation method to be rated as low risk; one article did not mention that the random method was evaluated as the risk of bias was not clear; one article was not randomly rated as high-risk bias. (2) In terms of allocation concealment, 12 articles implemented allocation concealment and were rated as low risk of bias; two articles did not report allocation concealment, and the risk of bias was unclear. (3) In terms of the blind method of subjects and researchers, four studies did not use the blind method for subjects and researchers and were rated as high risk of bias; ten studies were double-blinded and rated as low-risk bias. (4) In terms of blinding of outcome evaluators, two studies did not use blinding for outcome evaluators, which was rated as high risk of bias; two studies were not mentioned, and the risk of bias was not clear. Ten studies also used blinding for outcome evaluators, which was rated as low risk of bias. (5) In terms of incomplete data results, 12 articles showed complete data and were rated as low-risk bias; two studies did not mention issues such as loss of follow-up, and the risk of bias was unclear. (6) In terms of selective reporting of results, 13 studies did not find selective reporting of results, which was rated as low risk of bias; one study did not clarify the pre-study indicators, the selective reporting of the results was unclear, and the risk of bias was unclear. (7) In terms of other sources of bias, 14 studies found no other bias and were rated as low risk of bias.</p></sec><sec id="Sec11"><title>Meta-analysis</title><sec id="Sec12"><title>Effect of norepinephrine on 28-day mortality rate in patients</title><p id="Par17">The 28-day mortality rate was analyzed in 8 RCTs. The overall analysis using a fixed-effect model (<inline-formula id="IEq4"><alternatives><tex-math id="M7">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${I}^{2}$$\end{document}</tex-math><mml:math id="M8"><mml:msup><mml:mrow><mml:mi>I</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msup></mml:math><inline-graphic xlink:href="11845_2024_3827_Article_IEq4.gif"/></alternatives></inline-formula> = 0%) showed that the 28-day mortality rate in the norepinephrine group was significantly lower than that in the control group (RR&#x02009;=&#x02009;0.92; 95% CI, 0.86&#x02009;~&#x02009;0.99; <italic>P</italic>&#x02009;=&#x02009;0.03; Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>a).<fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p><bold>a</bold> The effect of norepinephrine on 28-day mortality. <bold>b</bold> The effect of norepinephrine on hospital mortality</p></caption><graphic xlink:href="11845_2024_3827_Fig2_HTML" id="MO2"/></fig></p></sec><sec id="Sec13"><title>Effect of norepinephrine on in-hospital mortality rate in patients</title><p id="Par18">The in-hospital mortality rate in 7 RCTs using the fixed-effect model (<inline-formula id="IEq5"><alternatives><tex-math id="M9">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${I}^{2}$$\end{document}</tex-math><mml:math id="M10"><mml:msup><mml:mrow><mml:mi>I</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msup></mml:math><inline-graphic xlink:href="11845_2024_3827_Article_IEq5.gif"/></alternatives></inline-formula> = 23%) revealed that it was lower in the norepinephrine group than in the control group, yet without statistical significance (RR&#x02009;=&#x02009;0.97; 95% CI, 0.90&#x02009;~&#x02009;1.04; <italic>P</italic>&#x02009;=&#x02009;0.4; Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>b).</p></sec><sec id="Sec14"><title>Effect of norepinephrine on 90-day mortality rate in patients</title><p id="Par19">The 90-day mortality rate analyzed in 4 RCTs using the fixed-effect model (<inline-formula id="IEq6"><alternatives><tex-math id="M11">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${I}^{2}$$\end{document}</tex-math><mml:math id="M12"><mml:msup><mml:mrow><mml:mi>I</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msup></mml:math><inline-graphic xlink:href="11845_2024_3827_Article_IEq6.gif"/></alternatives></inline-formula> = 0%) indicated a lower rate in the norepinephrine group than that in the control group, without statistical significance (RR&#x02009;=&#x02009;1.07; 95% CI, 0.98&#x02009;~&#x02009;1.18; <italic>P</italic>&#x02009;=&#x02009;0.15; Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>a).<fig id="Fig3"><label>Fig.&#x000a0;3</label><caption><p><bold>a</bold> The effect of norepinephrine on 90-day mortality. <bold>b</bold> The effect of norepinephrine on hospital length of stay. <bold>c</bold> The effect of norepinephrine on ICU length of stay</p></caption><graphic xlink:href="11845_2024_3827_Fig3_HTML" id="MO3"/></fig></p></sec><sec id="Sec15"><title>Effect of norepinephrine on length of hospital stay in patients</title><p id="Par20">The length of hospital stay was analyzed in 6 RCTs. The overall analysis using the fixed-effect model (<inline-formula id="IEq7"><alternatives><tex-math id="M13">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${I}^{2}$$\end{document}</tex-math><mml:math id="M14"><mml:msup><mml:mrow><mml:mi>I</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msup></mml:math><inline-graphic xlink:href="11845_2024_3827_Article_IEq7.gif"/></alternatives></inline-formula> = 25%) showed no difference in the length of hospital stay between the norepinephrine group and the control group (MD&#x02009;=&#x02009;0.03; 95% CI,&#x02009;&#x02212;&#x02009;1.13&#x02009;~&#x02009;1.18; <italic>P</italic>&#x02009;=&#x02009;0.96; Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>b).</p></sec><sec id="Sec16"><title>Effect of norepinephrine on length of stay in ICU in patients</title><p id="Par21">The analysis was also performed in 7 RCTs by employing a fixed-effect model (<inline-formula id="IEq8"><alternatives><tex-math id="M15">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${I}^{2}$$\end{document}</tex-math><mml:math id="M16"><mml:msup><mml:mrow><mml:mi>I</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msup></mml:math><inline-graphic xlink:href="11845_2024_3827_Article_IEq8.gif"/></alternatives></inline-formula> = 8%). It was found that the length of stay in the ICU of the norepinephrine group was significantly less than that of the control group (MD&#x02009;=&#x02009;&#x02009;&#x02212;&#x02009;1.03; 95% CI,&#x02009;&#x02212;&#x02009;1.85 to approximately&#x02009;&#x02212;&#x02009;0.21; <italic>P</italic>&#x02009;=&#x02009;0.01; Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>c).</p></sec><sec id="Sec17"><title>Effect of norepinephrine on the incidence of arrhythmia in patients</title><p id="Par22">By using a fixed-effect model (<inline-formula id="IEq9"><alternatives><tex-math id="M17">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${I}^{2}$$\end{document}</tex-math><mml:math id="M18"><mml:msup><mml:mrow><mml:mi>I</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msup></mml:math><inline-graphic xlink:href="11845_2024_3827_Article_IEq9.gif"/></alternatives></inline-formula> = 46%) for analysis in 8 RCTs, the incidence of arrhythmia in the norepinephrine group was observed to be significantly lower than that in the control group (RR&#x02009;=&#x02009;0.54; 95% CI, 0.45&#x02009;~&#x02009;0.64; <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001; Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>a).<fig id="Fig4"><label>Fig.&#x000a0;4</label><caption><p><bold>a</bold> The effect of norepinephrine on the incidence of arrhythmia. <bold>b</bold> The effect of norepinephrine on the rate of achieved the target mean arterial pressure</p></caption><graphic xlink:href="11845_2024_3827_Fig4_HTML" id="MO4"/></fig></p></sec><sec id="Sec18"><title>Effect of norepinephrine on the rate of achieving target MAP in patients</title><p id="Par23">The rate of achieving target MAP was analyzed in 3 RCTs using a random-effect model (<inline-formula id="IEq10"><alternatives><tex-math id="M19">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${I}^{2}$$\end{document}</tex-math><mml:math id="M20"><mml:msup><mml:mrow><mml:mi>I</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msup></mml:math><inline-graphic xlink:href="11845_2024_3827_Article_IEq10.gif"/></alternatives></inline-formula> = 92%) indicated no significant difference in the rate between the norepinephrine group and the control group (RR&#x02009;=&#x02009;1.27; 95% CI, 0.72&#x02009;~&#x02009;2.26; <italic>P</italic>&#x02009;=&#x02009;0.41; Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>b).</p></sec></sec></sec><sec id="Sec19"><title>Discussion</title><p id="Par24">In this study, 14 RCTs, involving 5028 cases, on the efficacy and safety of norepinephrine were included for meta-analysis. Corresponding results showed that the use of norepinephrine in patients with septic shock was negatively correlated with the 28-day mortality, length of stay in ICU, and incidence of arrhythmia. It suggests that norepinephrine can effectively reduce the mortality rate of patients with septic shock and alleviate their disease burden, accompanied by a relatively low incidence of side effects such as arrhythmia. However, this study failed to find any statistically significant differences in the improvement of in-hospital mortality rate, 90-day mortality rate, length of hospital stay, and rate of achieving target MAP between norepinephrine and other vasopressor agents in the treatment of septic shock.</p><p id="Par25">By using the Cochrane risk of bias tool, the quality of evidence in outcome measures varied from moderate to high, but the risk of bias in each field of most trials was low or unclear. Only four trials showed a high risk of performance bias due to the open-labeled design in two studies [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR25">25</xref>], and no blinding of the outcome measures in the remaining two studies [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]. Except for one study with randomization based on odd or even days, all the other trials were classified as low-risk in terms of random sequence generation [<xref ref-type="bibr" rid="CR25">25</xref>].</p><p id="Par26">Our meta-analysis of in-hospital mortality rate, 90-day mortality rate, and length of hospital stay showed no significant difference between norepinephrine and other vasopressor agents. It was consistent with the previous two meta-analyses, which showed that norepinephrine did not have a significant advantage in controlling patient mortality compared to other vasopressor agents such as dopamine, adrenaline, and phenylephrine [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR26">26</xref>]. However, meta-analysis based on studies of 28-day mortality rates revealed that norepinephrine can better control the mortality rate of septic shock patients compared to other vasopressor agents. It was similar to the conclusion reported in two reviews [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>], where norepinephrine was superior to dopamine in a 28-day mortality rate. It is speculated that compared with other vasopressor agents, norepinephrine can better control short-term mortality and timely alleviate the condition of illness, but requiring special attention to in-hospital care to lengthen the long-term life of patients.</p><p id="Par27">There is still some controversy about the view that norepinephrine shortens hospitalization time and ICU hospitalization time [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. Septic shock is prone to severe circulatory, cellular, and metabolic abnormalities and has a high mortality rate [<xref ref-type="bibr" rid="CR1">1</xref>]. Usually, patients with septic shock in the general hospital will be immediately transferred to the ICU for treatment. After the treatment is improved, they will be transferred out of the ICU ward. The time of treatment in the ICU is longer, but the time of hospitalization in the general ward is relatively short. During septic shock, norepinephrine should be given as early as possible, which is the key to the treatment of septic shock [<xref ref-type="bibr" rid="CR6">6</xref>]. Therefore, norepinephrine may shorten the length of ICU stay, but the difference in length of hospital stay may not be obvious. Contrary to the results of the length of hospital stay, users of norepinephrine had a shorter length of stay in ICU compared to other vasopressin users, with a statistical difference. However, prior meta-analysis revealed the opposite results as well, revealing that there was no significant difference in the length of stay in the ICU among patients [<xref ref-type="bibr" rid="CR20">20</xref>]. It may be explained by the inclusion of different studies, with more updated literature included in our meta-analysis than that in previous research. Meanwhile, our study also indicated that the use of norepinephrine resulted in better outcomes adverse reactions, with a lower incidence of arrhythmia in patients with norepinephrine.</p><p id="Par28">Accumulated data supports that maintaining target MAP and initiating early use of vasoactive agents are associated with the reduction of mortality in patients with septic shock [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>]. The SSC Guidelines emphasize that hemodynamic stability and sufficient perfusion of major organs should be achieved within 1 h [<xref ref-type="bibr" rid="CR31">31</xref>]. However, our meta-analysis showed that compared to other vasopressor agents, norepinephrine had no advantage in achieving target MAP. Moreover, there was significant heterogeneity (92%) in the results of achieving target MAP, which may be attributed to differences in the definition of achieving target MAP in different studies, the use of control drugs, and the dosage of drugs used. Due to the presence of significant heterogeneity, there might be no significant effect of norepinephrine on achieving target MAP. In addition, studies have found that in cases of refractory septic shock, other vasopressor agents can be applied to increase MAP in patients using norepinephrine [<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR33">33</xref>]. Similarly, in a prospective open-labeled study, patients who used other vasopressin and norepinephrine simultaneously achieved MAP of&#x02009;&#x0003e;&#x02009;65 mmHg faster than patients receiving norepinephrine alone [<xref ref-type="bibr" rid="CR34">34</xref>].</p><p id="Par29">Patients with septic shock have a critical condition, and treatment and nursing measures need to be closely linked. Therefore, ICU nurses should be proficient in understanding the nursing risks of patients with septic shock, enhance risk prevention awareness, and promptly administer norepinephrine [<xref ref-type="bibr" rid="CR8">8</xref>]. Meanwhile, during the use of norepinephrine, the use of a micro-injection pump can ensure a constant pump speed and maintain the steady-state blood drug concentration of norepinephrine. After administering vasopressor medication, dynamically evaluate the patient&#x02019;s blood pressure and heart rate. When the mean arterial pressure is less than 65 mmHg, report to the doctor in a timely manner to determine the reason for increasing the infusion rate of vasopressor medication [<xref ref-type="bibr" rid="CR7">7</xref>]. Early and effective fluid resuscitation in patients with septic shock is the key to reversing the condition. Effectively improving tissue perfusion, increasing oxygen delivery, and reducing organ failure, guided resuscitation based on hemodynamic evaluation can effectively improve prognosis [<xref ref-type="bibr" rid="CR6">6</xref>]. As the executor of fluid resuscitation treatment, ICU nurses play an important role in determining whether patients need to continue fluid replacement. They can first choose indicators that quickly reflect hemodynamic conditions such as mean arterial pressure, heart rate, urine volume, and lactate value to determine whether fluid replacement is necessary [<xref ref-type="bibr" rid="CR7">7</xref>]. In addition, continuous use of vasoconstrictors is an independent risk factor for secondary deep vein thrombosis (DVT) in the ICU; therefore, a combination of medication and mechanical prophylaxis should be used.</p><p id="Par30">However, this study still has some limitations. Firstly, children were not included due to limited available trials. Secondly, with literature retrieval in three databases, only 14 trials met the inclusion criteria, which might affect the stability of the results. These findings shall be confirmed by more clinical studies in the future. Thirdly, there may be unpublished or inaccessible reports that were not included, although we believed that all relevant studies should be included. Collectively, the findings of this study still need further supplementary validation based on more high-quality RCTs involving different age groups.</p></sec><sec id="Sec20"><title>Conclusion</title><p id="Par31">In conclusion, there is still not enough evidence to support that norepinephrine is superior to other vasopressor agents in terms of long-term mortality rate, achieving target MAP, and total length of hospital stay. However, the present meta-analysis highlights the superiority of norepinephrine in improving the 28-day mortality rate, shortening the length of stay in ICU, and reducing the incidence of arrhythmia, making it an effective and the safest option for septic shock. ICU nurses should be proficient in understanding the nursing risks of patients with septic shock, improve risk prevention awareness, and promptly administer norepinephrine. Anyway, larger-scale RCTs should be conducted to demonstrate the efficacy and safety of norepinephrine compared to other vasopressor agents. Additionally, it is recommended to perform appropriate allocation concealment and blinding to subjects and staff in future trials to reduce the risk of bias.</p></sec></body><back><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes notes-type="author-contribution"><title>Author contribution</title><p>Xu QY conceived and designed the study. Jin YH collected the data. Fu L helped with the data analysis and statistics. Li YY took part in drafting the manuscript. All authors read and approved the final manuscript.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>All data generated or analyzed during this study are included in this published article.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Consent for publication</title><p id="Par32">Not applicable.</p></notes><notes id="FPar2" notes-type="COI-statement"><title>Conflict of interest</title><p id="Par33">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Plevin</surname><given-names>R</given-names></name><name><surname>Callcut</surname><given-names>R</given-names></name></person-group><article-title>Update in sepsis guidelines: what is really new?</article-title><source>Trauma Surg Acute Care Open</source><year>2017</year><volume>2</volume><issue>1</issue><fpage>e000088</fpage><pub-id pub-id-type="doi">10.1136/tsaco-2017-000088</pub-id><pub-id pub-id-type="pmid">29766091</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Plevin R, Callcut R (2017) Update in sepsis guidelines: what is really new? Trauma Surg Acute Care Open 2(1):e000088. 10.1136/tsaco-2017-000088<pub-id pub-id-type="pmid">29766091</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Rudd</surname><given-names>KE</given-names></name><name><surname>Kissoon</surname><given-names>N</given-names></name><name><surname>Limmathurotsakul</surname><given-names>D</given-names></name><etal/></person-group><article-title>The global burden of sepsis: barriers and potential solutions</article-title><source>Crit Care</source><year>2018</year><volume>22</volume><issue>1</issue><fpage>232</fpage><pub-id pub-id-type="doi">10.1186/s13054-018-2157-z</pub-id><pub-id pub-id-type="pmid">30243300</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Rudd KE, Kissoon N, Limmathurotsakul D and others (2018) The global burden of sepsis: barriers and potential solutions. Crit Care 22(1):232. 10.1186/s13054-018-2157-z<pub-id pub-id-type="pmid">30243300</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Murray</surname><given-names>CJ</given-names></name><name><surname>Atkinson</surname><given-names>C</given-names></name><name><surname>Bhalla</surname><given-names>K</given-names></name><etal/></person-group><article-title>The state of US health, 1990&#x02013;2010: burden of diseases, injuries, and risk factors</article-title><source>JAMA</source><year>2013</year><volume>310</volume><issue>6</issue><fpage>591</fpage><lpage>608</lpage><pub-id pub-id-type="doi">10.1001/jama.2013.13805</pub-id><pub-id pub-id-type="pmid">23842577</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Murray CJ, Atkinson C, Bhalla K and others (2013) The state of US health, 1990&#x02013;2010: burden of diseases, injuries, and risk factors. JAMA 310(6):591&#x02013;608. 10.1001/jama.2013.13805<pub-id pub-id-type="pmid">23842577</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>G&#x000fc;l</surname><given-names>F</given-names></name><name><surname>Arslanta&#x0015f;</surname><given-names>MK</given-names></name><name><surname>Cinel</surname><given-names>&#x00130;</given-names></name><etal/></person-group><article-title>Changing definitions of sepsis</article-title><source>Turk J Anaesthesiol Reanim</source><year>2017</year><volume>45</volume><issue>3</issue><fpage>129</fpage><lpage>138</lpage><pub-id pub-id-type="doi">10.5152/TJAR.2017.93753</pub-id><pub-id pub-id-type="pmid">28752002</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">G&#x000fc;l F, Arslanta&#x0015f; MK, Cinel &#x00130; and others (2017) Changing definitions of sepsis. Turk J Anaesthesiol Reanim 45(3):129&#x02013;138. 10.5152/TJAR.2017.93753<pub-id pub-id-type="pmid">28752002</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Annane</surname><given-names>D</given-names></name><name><surname>Bellissant</surname><given-names>E</given-names></name><name><surname>Cavaillon</surname><given-names>JM</given-names></name></person-group><article-title>Septic shock</article-title><source>Lancet</source><year>2005</year><volume>365</volume><issue>9453</issue><fpage>63</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(04)17667-8</pub-id><pub-id pub-id-type="pmid">15639681</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Annane D, Bellissant E, Cavaillon JM (2005) Septic shock. Lancet 365(9453):63&#x02013;78. 10.1016/S0140-6736(04)17667-8<pub-id pub-id-type="pmid">15639681</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Evans</surname><given-names>L</given-names></name><name><surname>Rhodes</surname><given-names>A</given-names></name><name><surname>Alhazzani</surname><given-names>W</given-names></name><etal/></person-group><article-title>Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021</article-title><source>Intensive Care Med</source><year>2021</year><volume>47</volume><issue>11</issue><fpage>1181</fpage><lpage>1247</lpage><pub-id pub-id-type="doi">10.1007/s00134-021-06506-y</pub-id><pub-id pub-id-type="pmid">34599691</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Evans L, Rhodes A, Alhazzani W and others (2021) Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med 47(11):1181&#x02013;1247. 10.1007/s00134-021-06506-y<pub-id pub-id-type="pmid">34599691</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Singer</surname><given-names>M</given-names></name><name><surname>Deutschman</surname><given-names>CS</given-names></name><name><surname>Seymour</surname><given-names>CW</given-names></name><etal/></person-group><article-title>The third international consensus definitions for sepsis and septic shock (Sepsis-3)</article-title><source>JAMA</source><year>2016</year><volume>315</volume><issue>8</issue><fpage>801</fpage><lpage>810</lpage><pub-id pub-id-type="doi">10.1001/jama.2016.0287</pub-id><pub-id pub-id-type="pmid">26903338</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Singer M, Deutschman CS, Seymour CW and others (2016) The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 315(8):801&#x02013;810. 10.1001/jama.2016.0287<pub-id pub-id-type="pmid">26903338</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Rhodes</surname><given-names>A</given-names></name><name><surname>Evans</surname><given-names>LE</given-names></name><name><surname>Alhazzani</surname><given-names>W</given-names></name><etal/></person-group><article-title>Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016</article-title><source>Intensive Care Med</source><year>2017</year><volume>43</volume><issue>3</issue><fpage>304</fpage><lpage>377</lpage><pub-id pub-id-type="doi">10.1007/s00134-017-4683-6</pub-id><pub-id pub-id-type="pmid">28101605</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Rhodes A, Evans LE, Alhazzani W and others (2017) Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med 43(3):304&#x02013;377. 10.1007/s00134-017-4683-6<pub-id pub-id-type="pmid">28101605</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Yin</surname><given-names>L</given-names></name><name><surname>Hou</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>R</given-names></name><etal/></person-group><article-title>Efficacy of norepinephrine, dopamine or vasopressor in the management of septic shock and severe sepsis: a meta-analysis</article-title><source>Int J Clin Exp Med</source><year>2018</year><volume>11</volume><issue>11</issue><fpage>11383</fpage><lpage>11395</lpage></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Yin L, Hou L, Liu R and others (2018) Efficacy of norepinephrine, dopamine or vasopressor in the management of septic shock and severe sepsis: a meta-analysis. Int J Clin Exp Med 11(11):11383&#x02013;11395</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Sterne</surname><given-names>JAC</given-names></name><name><surname>Savovi&#x00107;</surname><given-names>J</given-names></name><name><surname>Page</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>RoB 2: a revised tool for assessing risk of bias in randomised trials</article-title><source>BMJ</source><year>2019</year><volume>28</volume><issue>366</issue><fpage>l4898</fpage><pub-id pub-id-type="doi">10.1136/bmj.l4898</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Sterne JAC, Savovi&#x00107; J, Page MJ and others (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 28(366):l4898. 10.1136/bmj.l4898</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Morelli</surname><given-names>A</given-names></name><name><surname>Ertmer</surname><given-names>C</given-names></name><name><surname>Lange</surname><given-names>M</given-names></name><etal/></person-group><article-title>Effects of short-term simultaneous infusion of dobutamine and terlipressin in patients with septic shock: the DOBUPRESS study</article-title><source>Br J Anaesth</source><year>2008</year><volume>100</volume><issue>4</issue><fpage>494</fpage><lpage>503</lpage><pub-id pub-id-type="doi">10.1093/bja/aen017</pub-id><pub-id pub-id-type="pmid">18308741</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Morelli A, Ertmer C, Lange M and others (2008) Effects of short-term simultaneous infusion of dobutamine and terlipressin in patients with septic shock: the DOBUPRESS study. Br J Anaesth 100(4):494&#x02013;503. 10.1093/bja/aen017<pub-id pub-id-type="pmid">18308741</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Morelli</surname><given-names>A</given-names></name><name><surname>Ertmer</surname><given-names>C</given-names></name><name><surname>Rehberg</surname><given-names>S</given-names></name><etal/></person-group><article-title>Continuous terlipressin versus vasopressin infusion in septic shock (TERLIVAP): a randomized, controlled pilot study</article-title><source>Crit Care</source><year>2009</year><volume>13</volume><issue>4</issue><fpage>R130</fpage><pub-id pub-id-type="doi">10.1186/cc7990</pub-id><pub-id pub-id-type="pmid">19664253</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Morelli A, Ertmer C, Rehberg S and others (2009) Continuous terlipressin versus vasopressin infusion in septic shock (TERLIVAP): a randomized, controlled pilot study. Crit Care 13(4):R130. 10.1186/cc7990<pub-id pub-id-type="pmid">19664253</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Annane</surname><given-names>D</given-names></name><name><surname>Vignon</surname><given-names>P</given-names></name><name><surname>Renault</surname><given-names>A</given-names></name><etal/></person-group><article-title>Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock: a randomised trial</article-title><source>Lancet</source><year>2007</year><volume>370</volume><issue>9588</issue><fpage>676</fpage><lpage>684</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(07)61344-0</pub-id><pub-id pub-id-type="pmid">17720019</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Annane D, Vignon P, Renault A and others (2007) Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock: a randomised trial. Lancet 370(9588):676&#x02013;684. 10.1016/S0140-6736(07)61344-0<pub-id pub-id-type="pmid">17720019</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Choudhury</surname><given-names>A</given-names></name><name><surname>Kedarisetty</surname><given-names>CK</given-names></name><name><surname>Vashishtha</surname><given-names>C</given-names></name><etal/></person-group><article-title>A randomized trial comparing terlipressin and noradrenaline in patients with cirrhosis and septic shock</article-title><source>Liver Int</source><year>2017</year><volume>37</volume><issue>4</issue><fpage>552</fpage><lpage>561</lpage><pub-id pub-id-type="doi">10.1111/liv.13252</pub-id><pub-id pub-id-type="pmid">27633962</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Choudhury A, Kedarisetty CK, Vashishtha C and others (2017) A randomized trial comparing terlipressin and noradrenaline in patients with cirrhosis and septic shock. Liver Int 37(4):552&#x02013;561. 10.1111/liv.13252<pub-id pub-id-type="pmid">27633962</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>De Backer</surname><given-names>D</given-names></name><name><surname>Biston</surname><given-names>P</given-names></name><name><surname>Devriendt</surname><given-names>J</given-names></name><etal/></person-group><article-title>Comparison of dopamine and norepinephrine in the treatment of shock</article-title><source>N Engl J Med</source><year>2010</year><volume>362</volume><issue>9</issue><fpage>779</fpage><lpage>789</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0907118</pub-id><pub-id pub-id-type="pmid">20200382</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">De Backer D, Biston P, Devriendt J and others (2010) Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med 362(9):779&#x02013;789. 10.1056/NEJMoa0907118<pub-id pub-id-type="pmid">20200382</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Gordon</surname><given-names>AC</given-names></name><name><surname>Mason</surname><given-names>AJ</given-names></name><name><surname>Thirunavukkarasu</surname><given-names>N</given-names></name><etal/></person-group><article-title>Effect of early vasopressin vs norepinephrine on kidney failure in patients with septic shock: the VANISH randomized clinical trial</article-title><source>JAMA</source><year>2016</year><volume>316</volume><issue>5</issue><fpage>509</fpage><lpage>518</lpage><pub-id pub-id-type="doi">10.1001/jama.2016.10485</pub-id><pub-id pub-id-type="pmid">27483065</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Gordon AC, Mason AJ, Thirunavukkarasu N and others (2016) Effect of early vasopressin vs norepinephrine on kidney failure in patients with septic shock: the VANISH randomized clinical trial. JAMA 316(5):509&#x02013;518. 10.1001/jama.2016.10485<pub-id pub-id-type="pmid">27483065</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Hajjar</surname><given-names>LA</given-names></name><name><surname>Zambolim</surname><given-names>C</given-names></name><name><surname>Belletti</surname><given-names>A</given-names></name><etal/></person-group><article-title>Vasopressin versus norepinephrine for the management of septic shock in cancer patients: the VANCS II randomized clinical trial</article-title><source>Crit Care Med</source><year>2019</year><volume>47</volume><issue>12</issue><fpage>1743</fpage><lpage>1750</lpage><pub-id pub-id-type="doi">10.1097/CCM.0000000000004023</pub-id><pub-id pub-id-type="pmid">31609774</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Hajjar LA, Zambolim C, Belletti A and others (2019) Vasopressin versus norepinephrine for the management of septic shock in cancer patients: the VANCS II randomized clinical trial. Crit Care Med 47(12):1743&#x02013;1750. 10.1097/CCM.0000000000004023<pub-id pub-id-type="pmid">31609774</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>ZM</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Kou</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Terlipressin versus norepinephrine as infusion in patients with septic shock: a multicentre, randomised, double-blinded trial</article-title><source>Intensive Care Med</source><year>2018</year><volume>44</volume><issue>11</issue><fpage>1816</fpage><lpage>1825</lpage><pub-id pub-id-type="doi">10.1007/s00134-018-5267-9</pub-id><pub-id pub-id-type="pmid">29971593</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Liu ZM, Chen J, Kou Q and others (2018) Terlipressin versus norepinephrine as infusion in patients with septic shock: a multicentre, randomised, double-blinded trial. Intensive Care Med 44(11):1816&#x02013;1825. 10.1007/s00134-018-5267-9<pub-id pub-id-type="pmid">29971593</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>C</given-names></name><name><surname>Papazian</surname><given-names>L</given-names></name><name><surname>Perrin</surname><given-names>G</given-names></name><etal/></person-group><article-title>Norepinephrine or dopamine for the treatment of hyperdynamic septic shock?</article-title><source>Chest</source><year>1993</year><volume>103</volume><issue>6</issue><fpage>1826</fpage><lpage>1831</lpage><pub-id pub-id-type="doi">10.1378/chest.103.6.1826</pub-id><pub-id pub-id-type="pmid">8404107</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Martin C, Papazian L, Perrin G and others (1993) Norepinephrine or dopamine for the treatment of hyperdynamic septic shock? Chest 103(6):1826&#x02013;1831. 10.1378/chest.103.6.1826<pub-id pub-id-type="pmid">8404107</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Morelli</surname><given-names>A</given-names></name><name><surname>Ertmer</surname><given-names>C</given-names></name><name><surname>Rehberg</surname><given-names>S</given-names></name><etal/></person-group><article-title>Phenylephrine versus norepinephrine for initial hemodynamic support of patients with septic shock: a randomized, controlled trial</article-title><source>Crit Care</source><year>2008</year><volume>12</volume><issue>6</issue><fpage>R143</fpage><pub-id pub-id-type="doi">10.1186/cc7121</pub-id><pub-id pub-id-type="pmid">19017409</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Morelli A, Ertmer C, Rehberg S and others (2008) Phenylephrine versus norepinephrine for initial hemodynamic support of patients with septic shock: a randomized, controlled trial. Crit Care 12(6):R143. 10.1186/cc7121<pub-id pub-id-type="pmid">19017409</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Myburgh</surname><given-names>JA</given-names></name><name><surname>Higgins</surname><given-names>A</given-names></name><name><surname>Jovanovska</surname><given-names>A</given-names></name><etal/></person-group><article-title>A comparison of epinephrine and norepinephrine in critically ill patients</article-title><source>Intensive Care Med</source><year>2008</year><volume>34</volume><issue>12</issue><fpage>2226</fpage><lpage>2234</lpage><pub-id pub-id-type="doi">10.1007/s00134-008-1219-0</pub-id><pub-id pub-id-type="pmid">18654759</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Myburgh JA, Higgins A, Jovanovska A and others (2008) A comparison of epinephrine and norepinephrine in critically ill patients. Intensive Care Med 34(12):2226&#x02013;2234. 10.1007/s00134-008-1219-0<pub-id pub-id-type="pmid">18654759</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>GP</given-names></name><name><surname>Grahe</surname><given-names>JS</given-names></name><name><surname>Sperry</surname><given-names>M</given-names></name><etal/></person-group><article-title>Efficacy and safety of dopamine versus norepinephrine in the management of septic shock</article-title><source>Shock</source><year>2010</year><volume>33</volume><issue>4</issue><fpage>375</fpage><lpage>380</lpage><pub-id pub-id-type="doi">10.1097/SHK.0b013e3181c6ba6f</pub-id><pub-id pub-id-type="pmid">19851126</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Patel GP, Grahe JS, Sperry M and others (2010) Efficacy and safety of dopamine versus norepinephrine in the management of septic shock. Shock 33(4):375&#x02013;380. 10.1097/SHK.0b013e3181c6ba6f<pub-id pub-id-type="pmid">19851126</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Permpikul</surname><given-names>C</given-names></name><name><surname>Tongyoo</surname><given-names>S</given-names></name><name><surname>Viarasilpa</surname><given-names>T</given-names></name><etal/></person-group><article-title>Early use of norepinephrine in septic shock resuscitation (CENSER). A randomized trial</article-title><source>Am J Respir Crit Care Med</source><year>2019</year><volume>199</volume><issue>9</issue><fpage>1097</fpage><lpage>1105</lpage><pub-id pub-id-type="doi">10.1164/rccm.201806-1034OC</pub-id><pub-id pub-id-type="pmid">30704260</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Permpikul C, Tongyoo S, Viarasilpa T and others (2019) Early use of norepinephrine in septic shock resuscitation (CENSER). A randomized trial. Am J Respir Crit Care Med 199(9):1097&#x02013;1105. 10.1164/rccm.201806-1034OC<pub-id pub-id-type="pmid">30704260</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Russell</surname><given-names>JA</given-names></name><name><surname>Walley</surname><given-names>KR</given-names></name><name><surname>Singer</surname><given-names>J</given-names></name><etal/></person-group><article-title>Vasopressin versus norepinephrine infusion in patients with septic shock</article-title><source>N Engl J Med</source><year>2008</year><volume>358</volume><issue>9</issue><fpage>877</fpage><lpage>887</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa067373</pub-id><pub-id pub-id-type="pmid">18305265</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Russell JA, Walley KR, Singer J and others (2008) Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 358(9):877&#x02013;887. 10.1056/NEJMoa067373<pub-id pub-id-type="pmid">18305265</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>JS</given-names></name><name><surname>Sperry</surname><given-names>M</given-names></name><name><surname>Singla</surname><given-names>S</given-names></name><name><surname>Elpern</surname><given-names>E</given-names></name><name><surname>Lateef</surname><given-names>O</given-names></name><name><surname>Balk</surname><given-names>RA</given-names></name></person-group><article-title>Efficacy and safety of dopamine versus norepinephrine in the management of septic shock [J]</article-title><source>Randomized Controlled Trial</source><year>2010</year><volume>33</volume><issue>4</issue><fpage>375</fpage><lpage>380</lpage><pub-id pub-id-type="doi">10.1097/SHK.0b013e3181c6ba6f</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Patel JS, Sperry M, Singla S, Elpern E, Lateef O, Balk RA (2010) Efficacy and safety of dopamine versus norepinephrine in the management of septic shock [J]. Randomized Controlled Trial 33(4):375&#x02013;380. 10.1097/SHK.0b013e3181c6ba6f</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Gamper</surname><given-names>G</given-names></name><name><surname>Havel</surname><given-names>C</given-names></name><name><surname>Arrich</surname><given-names>J</given-names></name><etal/></person-group><article-title>Vasopressors for hypotensive shock</article-title><source>Cochrane Database Syst Rev</source><year>2016</year><volume>2</volume><issue>2</issue><fpage>CD003709</fpage><pub-id pub-id-type="doi">10.1002/14651858.CD003709.pub4</pub-id><pub-id pub-id-type="pmid">26878401</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">Gamper G, Havel C, Arrich J and others (2016) Vasopressors for hypotensive shock. Cochrane Database Syst Rev 2(2):CD003709. 10.1002/14651858.CD003709.pub4<pub-id pub-id-type="pmid">26878401</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Avni</surname><given-names>T</given-names></name><name><surname>Lador</surname><given-names>A</given-names></name><name><surname>Lev</surname><given-names>S</given-names></name><etal/></person-group><article-title>Vasopressors for the treatment of septic shock: systematic review and meta-analysis</article-title><source>PLoS ONE</source><year>2015</year><volume>10</volume><issue>8</issue><fpage>e0129305</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0129305</pub-id><pub-id pub-id-type="pmid">26237037</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Avni T, Lador A, Lev S and others (2015) Vasopressors for the treatment of septic shock: systematic review and meta-analysis. PLoS ONE 10(8):e0129305. 10.1371/journal.pone.0129305<pub-id pub-id-type="pmid">26237037</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Vasu</surname><given-names>TS</given-names></name><name><surname>Cavallazzi</surname><given-names>R</given-names></name><name><surname>Hirani</surname><given-names>A</given-names></name><etal/></person-group><article-title>Norepinephrine or dopamine for septic shock: systematic review of randomized clinical trials</article-title><source>J Intensive Care Med</source><year>2012</year><volume>27</volume><issue>3</issue><fpage>172</fpage><lpage>178</lpage><pub-id pub-id-type="doi">10.1177/0885066610396312</pub-id><pub-id pub-id-type="pmid">21436167</pub-id>
</element-citation><mixed-citation id="mc-CR28" publication-type="journal">Vasu TS, Cavallazzi R, Hirani A and others (2012) Norepinephrine or dopamine for septic shock: systematic review of randomized clinical trials. J Intensive Care Med 27(3):172&#x02013;178. 10.1177/0885066610396312<pub-id pub-id-type="pmid">21436167</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>D&#x000fc;nser</surname><given-names>MW</given-names></name><name><surname>Ruokonen</surname><given-names>E</given-names></name><name><surname>Pettil&#x000e4;</surname><given-names>V</given-names></name><etal/></person-group><article-title>Association of arterial blood pressure and vasopressor load with septic shock mortality: a post hoc analysis of a multicenter trial</article-title><source>Crit Care</source><year>2009</year><volume>13</volume><issue>6</issue><fpage>R181</fpage><pub-id pub-id-type="doi">10.1186/cc8167</pub-id><pub-id pub-id-type="pmid">19917106</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">D&#x000fc;nser MW, Ruokonen E, Pettil&#x000e4; V and others (2009) Association of arterial blood pressure and vasopressor load with septic shock mortality: a post hoc analysis of a multicenter trial. Crit Care 13(6):R181. 10.1186/cc8167<pub-id pub-id-type="pmid">19917106</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Beck</surname><given-names>V</given-names></name><name><surname>Chateau</surname><given-names>D</given-names></name><name><surname>Bryson</surname><given-names>GL</given-names></name><etal/></person-group><article-title>Timing of vasopressor initiation and mortality in septic shock: a cohort study</article-title><source>Crit Care</source><year>2014</year><volume>18</volume><issue>3</issue><fpage>R97</fpage><pub-id pub-id-type="doi">10.1186/cc13868</pub-id><pub-id pub-id-type="pmid">24887489</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Beck V, Chateau D, Bryson GL and others (2014) Timing of vasopressor initiation and mortality in septic shock: a cohort study. Crit Care 18(3):R97. 10.1186/cc13868<pub-id pub-id-type="pmid">24887489</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Levy</surname><given-names>MM</given-names></name><name><surname>Evans</surname><given-names>LE</given-names></name><name><surname>Rhodes</surname><given-names>A</given-names></name></person-group><article-title>The surviving sepsis campaign bundle: 2018 update</article-title><source>Intensive Care Med</source><year>2018</year><volume>44</volume><issue>6</issue><fpage>925</fpage><lpage>928</lpage><pub-id pub-id-type="doi">10.1007/s00134-018-5085-0</pub-id><pub-id pub-id-type="pmid">29675566</pub-id>
</element-citation><mixed-citation id="mc-CR31" publication-type="journal">Levy MM, Evans LE, Rhodes A (2018) The surviving sepsis campaign bundle: 2018 update. Intensive Care Med 44(6):925&#x02013;928. 10.1007/s00134-018-5085-0<pub-id pub-id-type="pmid">29675566</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Malay</surname><given-names>MB</given-names></name><name><surname>Ashton</surname><given-names>RC</given-names><suffix>Jr</suffix></name><name><surname>Landry</surname><given-names>DW</given-names></name><etal/></person-group><article-title>Low-dose vasopressin in the treatment of vasodilatory septic shock</article-title><source>J Trauma.</source><year>1999</year><volume>47</volume><issue>4</issue><fpage>699</fpage><lpage>703</lpage><pub-id pub-id-type="doi">10.1097/00005373-199910000-00014</pub-id><pub-id pub-id-type="pmid">10528604</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Malay MB, Ashton RC Jr, Landry DW and others (1999) Low-dose vasopressin in the treatment of vasodilatory septic shock. J Trauma. 47(4):699&#x02013;703. 10.1097/00005373-199910000-00014. discussion 703-705<pub-id pub-id-type="pmid">10528604</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Tsuneyoshi</surname><given-names>I</given-names></name><name><surname>Yamada</surname><given-names>H</given-names></name><name><surname>Kakihana</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Hemodynamic and metabolic effects of low-dose vasopressin infusions in vasodilatory septic shock</article-title><source>Crit Care Med</source><year>2001</year><volume>29</volume><issue>3</issue><fpage>487</fpage><lpage>493</lpage><pub-id pub-id-type="doi">10.1097/00003246-200103000-00004</pub-id><pub-id pub-id-type="pmid">11373409</pub-id>
</element-citation><mixed-citation id="mc-CR33" publication-type="journal">Tsuneyoshi I, Yamada H, Kakihana Y and others (2001) Hemodynamic and metabolic effects of low-dose vasopressin infusions in vasodilatory septic shock. Crit Care Med 29(3):487&#x02013;493. 10.1097/00003246-200103000-00004<pub-id pub-id-type="pmid">11373409</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Hammond</surname><given-names>DA</given-names></name><name><surname>Ficek</surname><given-names>OA</given-names></name><name><surname>Painter</surname><given-names>JT</given-names></name><etal/></person-group><article-title>Prospective open-label trial of early concomitant vasopressin and norepinephrine therapy versus initial norepinephrine monotherapy in septic shock</article-title><source>Pharmacotherapy</source><year>2018</year><volume>38</volume><issue>5</issue><fpage>531</fpage><lpage>538</lpage><pub-id pub-id-type="doi">10.1002/phar.2105</pub-id><pub-id pub-id-type="pmid">29600824</pub-id>
</element-citation><mixed-citation id="mc-CR34" publication-type="journal">Hammond DA, Ficek OA, Painter JT and others (2018) Prospective open-label trial of early concomitant vasopressin and norepinephrine therapy versus initial norepinephrine monotherapy in septic shock. Pharmacotherapy 38(5):531&#x02013;538. 10.1002/phar.2105<pub-id pub-id-type="pmid">29600824</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>